These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 22069631)

  • 1. Exfoliative toxins of Staphylococcus aureus.
    Bukowski M; Wladyka B; Dubin G
    Toxins (Basel); 2010 May; 2(5):1148-65. PubMed ID: 22069631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus.
    Ladhani S
    FEMS Immunol Med Microbiol; 2003 Nov; 39(2):181-9. PubMed ID: 14625102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staphylococcal exfoliative toxins: "molecular scissors" of bacteria that attack the cutaneous defense barrier in mammals.
    Nishifuji K; Sugai M; Amagai M
    J Dermatol Sci; 2008 Jan; 49(1):21-31. PubMed ID: 17582744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxin involvement in staphylococcal scalded skin syndrome.
    Lina G; Gillet Y; Vandenesch F; Jones ME; Floret D; Etienne J
    Clin Infect Dis; 1997 Dec; 25(6):1369-73. PubMed ID: 9431380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins.
    Yamasaki O; Yamaguchi T; Sugai M; Chapuis-Cellier C; Arnaud F; Vandenesch F; Etienne J; Lina G
    J Clin Microbiol; 2005 Apr; 43(4):1890-3. PubMed ID: 15815014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staphylococcal epidermolysins.
    Prévost G; Couppié P; Monteil H
    Curr Opin Infect Dis; 2003 Apr; 16(2):71-6. PubMed ID: 12734438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome.
    Ladhani S; Joannou CL; Lochrie DP; Evans RW; Poston SM
    Clin Microbiol Rev; 1999 Apr; 12(2):224-42. PubMed ID: 10194458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1.
    Amagai M; Matsuyoshi N; Wang ZH; Andl C; Stanley JR
    Nat Med; 2000 Nov; 6(11):1275-7. PubMed ID: 11062541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial Resistance and Molecular Analysis of
    Choi JH; Lee H; Choi EH
    J Korean Med Sci; 2021 Jan; 36(3):e22. PubMed ID: 33463096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin findings of Staphylococcus aureus toxin-mediated infection in relation to toxin encoding genes.
    Courjon J; Hubiche T; Phan A; Tristan A; Bès M; Vandenesch F; Etienne J; Del Giudice P; Gillet Y
    Pediatr Infect Dis J; 2013 Jul; 32(7):727-30. PubMed ID: 23446443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Causative agent of impetigo: staphylococcal exfoliative toxin and regulation of the toxin production in Staphylococcus aureus].
    Sakurai S
    Nihon Saikingaku Zasshi; 1996 Aug; 51(3):813-22. PubMed ID: 8840812
    [No Abstract]   [Full Text] [Related]  

  • 12. Producibility of exfoliative toxin and staphylococcal coagulase types of Staphylococcus aureus strains isolated from skin infections and atopic dermatitis.
    Kanzaki H; Ueda M; Morishita Y; Akiyama H; Arata J; Kanzaki S
    Dermatology; 1997; 195(1):6-9. PubMed ID: 9267729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Removal of amino-terminal extracellular domains of desmoglein 1 by staphylococcal exfoliative toxin is sufficient to initiate epidermal blister formation.
    Nishifuji K; Shimizu A; Ishiko A; Iwasaki T; Amagai M
    J Dermatol Sci; 2010 Sep; 59(3):184-91. PubMed ID: 20728315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome.
    Hanakawa Y; Schechter NM; Lin C; Garza L; Li H; Yamaguchi T; Fudaba Y; Nishifuji K; Sugai M; Amagai M; Stanley JR
    J Clin Invest; 2002 Jul; 110(1):53-60. PubMed ID: 12093888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Staphylococcus aureus exfoliative toxins are not bacterial superantigens.
    Plano LR; Gutman DM; Woischnik M; Collins CM
    Infect Immun; 2000 May; 68(5):3048-52. PubMed ID: 10769013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staphylococcal toxins in human disease.
    Arbuthnott JP; Coleman DC; de Azavedo JS
    Soc Appl Bacteriol Symp Ser; 1990; 19():101S-107S. PubMed ID: 2119059
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of blister formation by staphylococcal toxins.
    Hanakawa Y; Stanley JR
    J Biochem; 2004 Dec; 136(6):747-50. PubMed ID: 15671483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An inhibitor of Staphylococcus aureus exfoliative toxin.
    Al-Sulami AA; Al-Rubiay KK; Affat AM
    East Mediterr Health J; 2001; 7(1-2):121-7. PubMed ID: 12596961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staphylococcal cutaneous infections: invasion, evasion and aggression.
    Iwatsuki K; Yamasaki O; Morizane S; Oono T
    J Dermatol Sci; 2006 Jun; 42(3):203-14. PubMed ID: 16679003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical syndromes caused by staphylococcal epidermolytic toxin.
    Edlich RF; Horowitz JH; Nichter LS; Silloway KA; Morgan RF
    Compr Ther; 1985 Apr; 11(4):45-8. PubMed ID: 3159536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.